EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans

Dolly Andrea Caicedo iD, Clara Pérez-Mañá iD, Magí Farré iD, Esther Papaseit

Pharmaceutics · 01.03.2025 · 17 (3) · 319

DOI: 10.3390/pharmaceutics17030319 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 01.03.2025. Verfasst von Dolly Andrea Caicedo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Cany…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII, Fondo de Investigación en Salud [FIS]-Fondo Europeo de Desarrollo Regional [FEDER], Generalitat de Catalunya (AGAUR), Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs, other approved prescription drugs, and other substances of abuse. Thus, identifying the enzymes metabolizing cannabinoid drugs and their relationship with other prescription drugs is crucial for understanding the potential interactions and effects of their simultaneous use. This article offers a comprehensive review of cannabis and the pharmacokinetic interactions between cannabis products, cannabis prescription drugs, and other approved prescription drugs, as well as other substances of abuse. It also compiles existing evidence of these interactions and describes the clinical outcomes associated with the inhibition or induction of various enzymes.

Schlagwörter

Stichwörter der Autor:innen

CBDTHCcannabidiolcannabisdrug interactionsmedicinespharmacokineticstetrahydrocannabinol

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Canyet, s/n, 08916 Badalona, Spain.
  • Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Bellaterra, 08193 Cerdanyola del Vallès, Spain.

ORCID-Profile: Dolly Andrea Caicedo, Clara Pérez-Mañá, Magí Farré

Förderung

  • Instituto de Salud Carlos III (ISCIII, Fondo de Investigación en Salud [FIS]-Fondo Europeo de Desarrollo Regional [FEDER]
  • Generalitat de Catalunya (AGAUR)
  • Instituto de Salud Carlos III

Zitieren

APA

Caicedo, D. A., Pérez-Mañá, C., Farré, M., & Papaseit, E. (2025). An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans. Pharmaceutics, 17(3), 319. https://doi.org/10.3390/pharmaceutics17030319

Vancouver

Caicedo DA, Pérez-Mañá C, Farré M, Papaseit E. An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans. Pharmaceutics. 2025;17(3):319. doi:10.3390/pharmaceutics17030319

BibTeX
@article{Caicedo2025,
  author = {Caicedo, Dolly Andrea and Pérez-Mañá, Clara and Farré, Magí and Papaseit, Esther},
  title = {An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {319},
  doi = {10.3390/pharmaceutics17030319}
}
Kostenlos starten →